Founded in 2025 and based in Schlieren, ALP Bio is building a hybrid platform that combines human tonsil-derived immune organoid readouts with generative AI to predict and reduce anti-drug antibody risk earlier in antibody discovery and development. The platform is designed to support lead candidate screening, ADA risk stratification, and sequence optimisation while preserving therapeutic function. ALP Bio emphasizes integrating experimentally measured human immune biology with machine learning models to bring more clinically relevant signal into earlier decision-making. The team plans to scale lab automation and throughput and pursue early partner projects with pharmaceutical and biotech teams. Financially, the company recently completed a €1.9 million pre-Seed round to fund platform expansion and commercial engagement in Switzerland and the US.

Total raised

$2M

Funding rounds

2

Latest round

Equity

Latest activity

Jul 2026